Starzyńska Anna, Sejda Aleksandra, Adamska Paulina, Marvaso Giulia, Sakowicz-Burkiewicz Monika, Adamski Łukasz, Jereczek-Fossa Barbara A
Department of Oral Surgery, Medical University of Gdansk, Gdansk, Poland.
Department of Pathomorphology, University of Warmia and Mazury, Olsztyn, Poland.
Arch Med Sci. 2020 Nov 13;17(1):207-217. doi: 10.5114/aoms.2020.100780. eCollection 2021.
Over 260,000 (2013) new oral squamous cell carcinoma (OSCC) cases are reported annually worldwide. Despite development in OSCC management, the outcome is still unsatisfactory. Identification of new molecular markers may be of use in prevention, prognosis, and choice of an appropriate therapy. The intracellular molecular signalling pathway of phosphatidyl-inositol-3-kinase is involved in the process of cell growth, differentiation, migration, and survival. The main components of this pathway: PIK3CA (phosphatidylinositol-4,5-bisphosphate-3-kinase catalytic subunit α), PTEN (phosphatase and tensin homologue deleted on chromosome 10), and AKT (serine-threonine kinase) are potential objects of research when introducing new therapeutic agents. The aim of this paper is to evaluate the , , and gene mutations as prognostic factors in OSCC and to describe their role in aggressive disease progression. This is crucial for oral cancer biology understanding and for indicating which direction new clinical treatments should take.
全球每年报告超过26万例(2013年数据)新的口腔鳞状细胞癌(OSCC)病例。尽管OSCC的治疗有所进展,但治疗结果仍不尽人意。鉴定新的分子标志物可能有助于预防、判断预后以及选择合适的治疗方法。磷脂酰肌醇-3-激酶的细胞内分子信号通路参与细胞生长、分化、迁移和存活过程。该信号通路的主要组成部分:PIK3CA(磷脂酰肌醇-4,5-二磷酸-3-激酶催化亚基α)、PTEN(第10号染色体缺失的磷酸酶和张力蛋白同源物)和AKT(丝氨酸-苏氨酸激酶)是引入新治疗药物时潜在的研究对象。本文旨在评估 、 和 基因突变作为OSCC预后因素的情况,并描述它们在侵袭性疾病进展中的作用。这对于理解口腔癌生物学以及指明新的临床治疗方向至关重要。
(注:原文中部分基因名称处有缺失内容,翻译时保留了原文格式。)